Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more
Daewon Pharm (003220) - Total Assets
Latest total assets as of September 2025: ₩606.37 Billion KRW
Based on the latest financial reports, Daewon Pharm (003220) holds total assets worth ₩606.37 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Daewon Pharm - Total Assets Trend (2011–2024)
This chart illustrates how Daewon Pharm’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Daewon Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Daewon Pharm's total assets of ₩606.37 Billion consist of 44.2% current assets and 55.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.9% |
| Accounts Receivable | ₩73.36 Billion | 12.6% |
| Inventory | ₩113.17 Billion | 19.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩49.15 Billion | 8.4% |
| Goodwill | ₩5.65 Billion | 1.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Daewon Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daewon Pharm's current assets represent 44.2% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2024, down from 12.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 19.4% of total assets.
Daewon Pharm Competitors by Total Assets
Key competitors of Daewon Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Daewon Pharm - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Daewon Pharm generates 1.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Daewon Pharm generates $ 2.44 in net profit.
Daewon Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 1.36 | 2.09 |
| Quick Ratio | 0.73 | 0.81 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩43.62 Billion | ₩ 74.83 Billion | ₩ 61.26 Billion |
Daewon Pharm - Advanced Valuation Insights
This section examines the relationship between Daewon Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.98 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 14.8% |
| Total Assets | ₩583.39 Billion |
| Market Capitalization | $93.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daewon Pharm's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daewon Pharm's assets grew by 14.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daewon Pharm (2011–2024)
The table below shows the annual total assets of Daewon Pharm from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩583.39 Billion | +14.84% |
| 2023-12-31 | ₩508.00 Billion | +12.00% |
| 2022-12-31 | ₩453.55 Billion | +5.58% |
| 2021-12-31 | ₩429.58 Billion | +28.15% |
| 2020-12-31 | ₩335.21 Billion | +2.35% |
| 2019-12-31 | ₩327.53 Billion | +18.91% |
| 2018-12-31 | ₩275.44 Billion | +21.23% |
| 2017-12-31 | ₩227.20 Billion | +5.83% |
| 2016-12-31 | ₩214.68 Billion | +10.23% |
| 2015-12-31 | ₩194.75 Billion | +7.82% |
| 2014-12-31 | ₩180.62 Billion | +12.79% |
| 2013-12-31 | ₩160.14 Billion | +8.85% |
| 2012-12-31 | ₩147.13 Billion | +4.80% |
| 2011-12-31 | ₩140.39 Billion | -- |